PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming 27th Annual H.C. Wainwright Global Investment Conference taking place on September 8-9, 2025, at the Lotte New York Palace Hotel, New York City.
PolyPid's fireside chat with H.C. Wainwright Managing Director, Equity Research, Brandon Folkes, will take place from 11:30 AM - 12:00 PM ET on Monday, September 8, 2025.
The PolyPid management team will participate in virtual and in-person one-on-one investor meetings during this event. Investors attending the event may request a one-on-one meeting with PolyPid through their H.C. Wainwright representative or e-mail This email address is being protected from spambots. You need JavaScript enabled to view it..
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. Following positive phase 3 results, New Drug Application (NDA) submission of D-PLEX₁₀₀, PolyPid's lead product candidate, for the prevention of abdominal colorectal surgical site infections, is expected in early 2026. In addition, the Company has an innovative pipeline in oncology, obesity and diabetes.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor & IR Contact:
Arx | Capital Markets
North American Equities Desk
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.78 |
| Daily Change: | -0.07 -1.82 |
| Daily Volume: | 49,382 |
| Market Cap: | US$62.860M |
November 12, 2025 September 30, 2025 September 17, 2025 September 16, 2025 September 02, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
